The file has to exist first
Classification of the product, localisation of the dossier and the filing itself. Until the registration is in place, nothing downstream can legally begin.
Partner with us
Entering Saudi Arabia is not one job. It is five — registration, importation, licensed storage, institutional listing, and a sales team that already holds the relationships. Most manufacturers assemble that from five suppliers and hope the seams hold. ATHEER PHARMA owns every one of them.
What entry actually requires
Each of these has to be done, in order, before your product reaches a patient in the Kingdom. Miss one and the rest stall — and the manufacturer, not the agent, carries the delay.
Classification of the product, localisation of the dossier and the filing itself. Until the registration is in place, nothing downstream can legally begin.
Import, clearance and release under a Saudi licence — held by the company whose name is on the registration, not borrowed from a third party.
Licensed, GDP-aligned storage, temperature-mapped, with a validated 2–8 °C chain for the lines that need one. SFDA licence WL-2023-DR-0043.
NUPCO, the Ministry of Health, the military and security health services, the specialist centres and the private hospital groups — each on its own terms and its own timetable.
People who already sit in front of the hospital pharmacist, the tender committee and the chain buyer. Relationships are not a launch cost that can be skipped.
One company, one contract, one accountable name — not five. Not a broker, not a freight agent, not a reseller.
Start the conversationWhat a partner gets
Three commitments, in the order they happen. Each one is done by our own people, in the Kingdom, under the licence that carries our name.
SFDA classification, dossier localisation and filing by our in-house regulatory team — end to end, including variations and listing. You are not handed a consultant's number and a status you cannot check.
A market analysis and a phased launch plan for your portfolio, in writing: which products go first, which channel opens when, and how the public and private routes are sequenced rather than attempted at once.
Licensed storage, a validated 2–8 °C cold chain and delivery into thirteen administrative regions on vehicles we own — which is why the delivery date we give is the one you get.
The market
Saudi Arabia is the largest pharmaceutical market in the Middle East and North Africa — roughly a third of regional demand, in one country, under one regulator.
Forecast Saudi pharmaceutical market for 2030
Roughly a third of all MENA pharmaceutical demand
Population, with rising chronic disease prevalence
SAR 44 billion ≈ US$11.8 billion. Source: Daleel, accessed August 2026.
Regional volume that elsewhere is split across a dozen markets sits here behind a single registration route. The work of entry is done once.
A population above 35 million with rising chronic disease prevalence — sustained demand for chronic therapy, devices and consumer health rather than one-off volume.
Healthcare capacity and local manufacturing are national objectives. A route that is Saudi-licensed, Saudi-staffed and able to point at locally made lines is on the right side of that policy — ours already includes THERAVÉ®, made in Saudi Arabia.
Serialisation and track & trace, enforcement of good distribution practice, stricter registration. Each raises the cost of an improvised route and favours distributors who are already licensed, audited and traceable. We operate RSD track & trace on that basis.
Evidence, not adjectives
None of this is a proposal. It is the operation as it stands today — and every figure below can be evidenced with the licence, the temperature record, the KPI or the batch trace.
On-time delivery against institutional KPI
Hospitals and medical cities served directly
Administrative regions within delivery scope
Cold chain validated end to end
Track and trace across the licensed supply chain
Already on this route
Exclusive and selective agreements across the United States, Europe, the United Kingdom, the GCC and inside the Kingdom.
One company owns every step
from the factory door
to the hospital shelf.
The distance is our problem, not the customer's. Every route ends at the patient.
Start the conversation
Send the product, the category and the country. If it belongs in this market we will say so and show you the route; if it does not, we will say that too.
Prefer to write directly? Partnership enquiries go straight to coo@atheerpharma.com, or by telephone on +966 13 814 1386. This form reaches the same desk — use whichever suits you.